Elissa C McIntosh1, Daniel A Nation1,2. 1. Department of Psychology, University of Southern California, Los Angeles, CA danation@usc.edu ecmcinto@usc.edu. 2. Department of Physiology and Neuroscience, University of Southern California, Los Angeles, CA.
Abstract
OBJECTIVE: To investigate relationships among type 2 diabetes treatment, Alzheimer's disease(AD) biomarkers, and risk for dementia. RESEARCH DESIGN AND METHODS: Participants were from the Alzheimer's Disease Neuroimaging Initiative (N = 1,289) and were dementia-free at baseline and underwent health assessment, cognitive testing, and MRI. A subset (n = 900) obtained a lumbar puncture to determine cerebrospinal fluid (CSF) phosphorylated tau (p-tau), total tau (t-tau), and β-amyloid 1-42 (Aβ1-42). Participants were grouped by fasting blood glucose and medication history: euglycemia (EU), prediabetes (PD), untreated diabetes (UD), and treated diabetes (TD). Relationships were investigated between treatment status and CSF biomarkers and risk for dementia. RESULTS: The UD group displayed greater p-tau, t-tau, and p-tau/Aβ1-42 levels than the EU, PD, and TD groups (P values <0.05) and higher t-tau/Aβ1-42 than the EU and PD groups (P values <0.05). The UD group progressed to dementia at higher rates than the EU group (hazard ratio 1.602 [95% CI 1.057-2.429]; P = 0.026). CONCLUSIONS: Treatment status may alter the relationship between type 2 diabetes and both AD biomarker profile and risk for dementia. UD is associated with elevated tau pathology and risk for dementia, whereas TD is not. Although this study is observational and therefore causality cannot be inferred, findings support the potential importance of treatment status in AD risk associated with type 2 diabetes.
OBJECTIVE: To investigate relationships among type 2 diabetes treatment, Alzheimer's disease(AD) biomarkers, and risk for dementia. RESEARCH DESIGN AND METHODS: Participants were from the Alzheimer's Disease Neuroimaging Initiative (N = 1,289) and were dementia-free at baseline and underwent health assessment, cognitive testing, and MRI. A subset (n = 900) obtained a lumbar puncture to determine cerebrospinal fluid (CSF) phosphorylated tau (p-tau), total tau (t-tau), and β-amyloid 1-42 (Aβ1-42). Participants were grouped by fasting blood glucose and medication history: euglycemia (EU), prediabetes (PD), untreated diabetes (UD), and treated diabetes (TD). Relationships were investigated between treatment status and CSF biomarkers and risk for dementia. RESULTS: The UD group displayed greater p-tau, t-tau, and p-tau/Aβ1-42 levels than the EU, PD, and TD groups (P values <0.05) and higher t-tau/Aβ1-42 than the EU and PD groups (P values <0.05). The UD group progressed to dementia at higher rates than the EU group (hazard ratio 1.602 [95% CI 1.057-2.429]; P = 0.026). CONCLUSIONS: Treatment status may alter the relationship between type 2 diabetes and both AD biomarker profile and risk for dementia. UD is associated with elevated tau pathology and risk for dementia, whereas TD is not. Although this study is observational and therefore causality cannot be inferred, findings support the potential importance of treatment status in AD risk associated with type 2 diabetes.
Authors: Emily C Edmonds; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: J Int Neuropsychol Soc Date: 2014-08-26 Impact factor: 2.892
Authors: Yael D Reijmer; Esther van den Berg; Carla Ruis; L Jaap Kappelle; Geert Jan Biessels Journal: Diabetes Metab Res Rev Date: 2010-10 Impact factor: 4.876
Authors: M S Beeri; J Schmeidler; J M Silverman; S Gandy; M Wysocki; C M Hannigan; D P Purohit; G Lesser; H T Grossman; V Haroutunian Journal: Neurology Date: 2008-09-02 Impact factor: 9.910
Authors: Angela M Abbatecola; Fabrizia Lattanzio; Anna M Molinari; Michele Cioffi; Luigi Mansi; Pierfrancesco Rambaldi; Luigi DiCioccio; Federico Cacciapuoti; Raffaele Canonico; Giuseppe Paolisso Journal: Diabetes Care Date: 2010-04-30 Impact factor: 19.112
Authors: Insa Feinkohl; Phyu Phyu Aung; Marketa Keller; Christine M Robertson; Joanne R Morling; Stela McLachlan; Ian J Deary; Brian M Frier; Mark W J Strachan; Jackie F Price Journal: Diabetes Care Date: 2013-10-08 Impact factor: 19.112
Authors: Jie Zheng; Min Xu; Venexia Walker; Jinqiu Yuan; Roxanna Korologou-Linden; Jamie Robinson; Peiyuan Huang; Stephen Burgess; Shiu Lun Au Yeung; Shan Luo; Michael V Holmes; George Davey Smith; Guang Ning; Weiqing Wang; Tom R Gaunt; Yufang Bi Journal: Diabetologia Date: 2022-07-29 Impact factor: 10.460
Authors: Johanna Thunell; Yi Chen; Geoffrey Joyce; Douglas Barthold; Paul G Shekelle; Roberta Diaz Brinton; Julie Zissimopoulos Journal: Alzheimers Dement Date: 2020-10-08 Impact factor: 21.566